Celgene Corp (CELG) 132.56 $CELG
Celgene Set to Possibly Rebound After Yesterday's Selloff of 1.73%
Comtex SmarTrend(R) - Mon Jul 27, 3:53PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 132.56 (-2.34)
Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.73% Sell Off
Comtex SmarTrend(R) - Mon Jul 27, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 132.56 (-2.34)
Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 309.43 (+9.40), GRUB: 31.01 (-2.78), XBI: 251.78 (-3.60), IBB: 373.58 (-4.00), REGN: 540.03 (-1.82), CELG: 132.56 (-2.34)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), LGND: 102.55 (+0.46), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82), EXEL: 5.44 (-0.15), CELG: 132.56 (-2.34)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 309.43 (+9.40), AMZN: 531.41 (+1.99), MON: 101.46 (-1.40), COP: 50.65 (-1.44), AMGN: 165.54 (+6.95), XOM: 79.26 (-0.68), SLB: 81.76 (-1.14), CELG: 132.56 (-2.34), RIG: 13.11 (-0.15), GILD: 110.54 (-2.29), DD: 56.73 (-0.21), PX: 111.82 (-1.16), CVX: 89.14 (-1.46), DOW: 45.63 (-0.34), REGN: 540.03 (-1.82)
FCX, CLF, BIIB, COF: Jim Cramer's Views
at The Street - Mon Jul 27, 12:00AM CDT
Jim Cramer shares his views on a really bad day and when a leader stumbles. Freeport McMoRan, Google, Biogen and Capital One are among the many stocks discussed here.
BIIB: 309.43 (+9.40), COF: 78.61 (-0.25), GILD: 110.54 (-2.29), FCX: 11.37 (-0.92), RCPT: 227.09 (-0.91), CLF: 2.40 (-0.06), REGN: 540.03 (-1.82), CELG: 132.56 (-2.34)
1 ETF That’s Crushing Even Warren Buffett
George Budwell, The Motley Fool - Motley Fool - Sat Jul 25, 6:07AM CDT
Source: Flickr via Fortune Live Media Berkshire Hathaway is a legendary holding company among investors due to its 50-year history of averaging a staggering 19% annual return . To put this amazing feat into context, Berkshire's average annual...
GILD: 110.54 (-2.29), IBB: 373.58 (-4.00), CELG: 132.56 (-2.34)
Biotech IPO Boom Gaining Thrust With NantKwest Debut
at Investor's Business Daily - Fri Jul 24, 5:33PM CDT
A hot market for biotech IPOs is about to get hotter with the upcoming debut of NantKwest, a developer of cancer therapies that could set a record for market valuation. NantKwest (NK) will be the 51st initial public offering in the health care field...
BBP: 35.48 (-0.35), BIIB: 309.43 (+9.40), BBC: 36.18 (-0.67), ADRO: 26.40 (-0.29), KITE: 68.86 (+0.14), NK: (), ALXN: 198.10 (-2.89), RCPT: 227.09 (-0.91), TEVA: 72.00 (+10.15), JUNO: 47.80 (-2.36), CELG: 132.56 (-2.34)
Cramer: Biogen's Horseman May Have Fallen Off, But These 3 Are Better
at The Street - Fri Jul 24, 1:08PM CDT
Jim Cramer answers viewers' questions on Biogen and weighs in on better alternatives. He also responds to questions on Ford and touches into the telecom players.
AMBA: 119.45 (-4.78), AMZN: 531.41 (+1.99), BIIB: 309.43 (+9.40), GPRO: 61.27 (-0.90), F: 14.55 (+0.16), ITEK: 16.76 (-0.89), FB: 94.17 (-2.78), GOOG: 627.26 (+3.70), CELG: 132.56 (-2.34), NFLX: 106.43 (-2.91), AGN: 326.98 (+18.77), T: 34.32 (+0.03), GILD: 110.54 (-2.29), S: 3.10 (-0.34), DTV: 93.55 (+1.36), GM: 31.05 (-0.01), TMUS: 36.50 (-0.90), TWTR: 34.70 (-0.72), VZ: 45.83 (-0.21), REGN: 540.03 (-1.82)
Biogen's Big-Volume Plunge Marks End Of 5-Year Run
at Investor's Business Daily - Fri Jul 24, 12:26PM CDT
Biogen's (BIIB) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech's quarterly revenue growth to come in well below consensus estimates. The company also cut its...
BIIB: 309.43 (+9.40), VRX: 257.30 (+5.38), LLY: 84.15 (-0.57), ABBV: 69.34 (+1.26), BMY: 64.30 (-1.68), CELG: 132.56 (-2.34)
When Leader Goes Down, Whole Sector Feels It
at The Street - Fri Jul 24, 10:24AM CDT
Biogen's weak numbers leave biotechs ailing.
BIIB: 309.43 (+9.40), COF: 78.61 (-0.25), GILD: 110.54 (-2.29), RCPT: 227.09 (-0.91), REGN: 540.03 (-1.82), CELG: 132.56 (-2.34)
Stocks Open Mixed And Wild; Maxim, Visa, Amazon Spike
at Investor's Business Daily - Fri Jul 24, 9:39AM CDT
Stocks set out in a tightly-mixed start Friday, with both the Nasdaq and S&P 500 trading about 1% lower so far for the week. The Nasdaq pulled up 0.3%. The Dow Jones industrial average managed a 0.1% gain. The S&P 500 hung out a fractional loss....
AMBA: 119.45 (-4.78), MXIM: 33.85 (+0.28), BIIB: 309.43 (+9.40), AMZN: 531.41 (+1.99), TRIP: 80.60 (-0.26), CELG: 132.56 (-2.34), JNPR: 27.43 (-0.11), CI: 145.90 (+0.18), ANTM: 151.50 (+0.64), V: 73.86 (-0.94), SAVE: 59.78 (-0.55), COF: 78.61 (-0.25), AAL: 40.14 (+0.51)
Celgene Delivers as Expected in Q2, but Raises New Questions
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 24, 9:10AM CDT
Source: Food and Drug Administration via Facebook. Biotech blue-chip stock Celgene (NASDAQ: CELG) knows only one gear when it comes to earnings season: overdrive. With the exception of the fourth-quarter of 2013, Celgene has topped Wall Street's...
CELG: 132.56 (-2.34)
Celgene posts 36% rise in Q2 2015 adjusted net income
M2 - Fri Jul 24, 5:37AM CDT
Biopharmaceutical company Celgene (NasdaqGS:CELG) on Thursday declared its adjusted net income of USD1,019m for the second quarter of 2015 .
CELG: 132.56 (-2.34), CELGZ: 2.00 (-0.06)
Celgene Rolling Along (but You Already Knew That)
Brian Orelli, The Motley Fool - Motley Fool - Thu Jul 23, 1:47PM CDT
The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week. But the details of where the...
RCPT: 227.09 (-0.91), ABBV: 69.34 (+1.26), CELG: 132.56 (-2.34)
Celgene (CELG) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Thu Jul 23, 1:11PM CDT
The following Celgene (CELG) conference call took place on July 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
CELG: 132.56 (-2.34)
Celgene Q2 Earnings & Revenues In Line, Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:26PM CDT
Celgene Corporation (CELG) reported second-quarter 2015 earnings of $1.08 per share (including stock-based compensation expenses and tax adjustments), in line with the Zacks Consensus Estimate.
RCPT: 227.09 (-0.91), JUNO: 47.80 (-2.36), AMAG: 65.07 (-5.37), CELG: 132.56 (-2.34)
Next Resistance Level for Celgene (CELG) is $141.45
Comtex SmarTrend(R) - Thu Jul 23, 10:18AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $137.52 and have already reached the first level of resistance at $139.86. Investors may be interested in a cross of the next upside pivot targets of $141.45 and $145.38.
CELG: 132.56 (-2.34)
Uptrend Call Working As Celgene Stock Rises 18.8% (CELG)
Comtex SmarTrend(R) - Thu Jul 23, 10:05AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on June 19th, 2015 at $117.12. In approximately 1 month, Celgene has returned 18.80% as of today's recent price of $139.14.
CELG: 132.56 (-2.34)
Valeant Earnings Soar On M&A, Organic Sales Growth
at Investor's Business Daily - Thu Jul 23, 8:37AM CDT
Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts' second-quarter revenue and earnings expectations. Valeant was one...
ENDP: 85.81 (+0.42), VRX: 257.30 (+5.38), SHPG: 259.11 (+6.54), RCPT: 227.09 (-0.91), LLY: 84.15 (-0.57), BMY: 64.30 (-1.68), CELG: 132.56 (-2.34)
Celgene Set to Possibly Rebound After Yesterday's Selloff of 1.73%
Comtex SmarTrend(R) - Mon Jul 27, 3:53PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 132.56 (-2.34)
Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.73% Sell Off
Comtex SmarTrend(R) - Mon Jul 27, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 132.56 (-2.34)
Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 309.43 (+9.40), GRUB: 31.01 (-2.78), XBI: 251.78 (-3.60), IBB: 373.58 (-4.00), REGN: 540.03 (-1.82), CELG: 132.56 (-2.34)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), LGND: 102.55 (+0.46), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82), EXEL: 5.44 (-0.15), CELG: 132.56 (-2.34)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 309.43 (+9.40), AMZN: 531.41 (+1.99), MON: 101.46 (-1.40), COP: 50.65 (-1.44), AMGN: 165.54 (+6.95), XOM: 79.26 (-0.68), SLB: 81.76 (-1.14), CELG: 132.56 (-2.34), RIG: 13.11 (-0.15), GILD: 110.54 (-2.29), DD: 56.73 (-0.21), PX: 111.82 (-1.16), CVX: 89.14 (-1.46), DOW: 45.63 (-0.34), REGN: 540.03 (-1.82)
FCX, CLF, BIIB, COF: Jim Cramer's Views
at The Street - Mon Jul 27, 12:00AM CDT
Jim Cramer shares his views on a really bad day and when a leader stumbles. Freeport McMoRan, Google, Biogen and Capital One are among the many stocks discussed here.
BIIB: 309.43 (+9.40), COF: 78.61 (-0.25), GILD: 110.54 (-2.29), FCX: 11.37 (-0.92), RCPT: 227.09 (-0.91), CLF: 2.40 (-0.06), REGN: 540.03 (-1.82), CELG: 132.56 (-2.34)
1 ETF That’s Crushing Even Warren Buffett
George Budwell, The Motley Fool - Motley Fool - Sat Jul 25, 6:07AM CDT
Source: Flickr via Fortune Live Media Berkshire Hathaway is a legendary holding company among investors due to its 50-year history of averaging a staggering 19% annual return . To put this amazing feat into context, Berkshire's average annual...
GILD: 110.54 (-2.29), IBB: 373.58 (-4.00), CELG: 132.56 (-2.34)
Biotech IPO Boom Gaining Thrust With NantKwest Debut
at Investor's Business Daily - Fri Jul 24, 5:33PM CDT
A hot market for biotech IPOs is about to get hotter with the upcoming debut of NantKwest, a developer of cancer therapies that could set a record for market valuation. NantKwest (NK) will be the 51st initial public offering in the health care field...
BBP: 35.48 (-0.35), BIIB: 309.43 (+9.40), BBC: 36.18 (-0.67), ADRO: 26.40 (-0.29), KITE: 68.86 (+0.14), NK: (), ALXN: 198.10 (-2.89), RCPT: 227.09 (-0.91), TEVA: 72.00 (+10.15), JUNO: 47.80 (-2.36), CELG: 132.56 (-2.34)
Cramer: Biogen's Horseman May Have Fallen Off, But These 3 Are Better
at The Street - Fri Jul 24, 1:08PM CDT
Jim Cramer answers viewers' questions on Biogen and weighs in on better alternatives. He also responds to questions on Ford and touches into the telecom players.
AMBA: 119.45 (-4.78), AMZN: 531.41 (+1.99), BIIB: 309.43 (+9.40), GPRO: 61.27 (-0.90), F: 14.55 (+0.16), ITEK: 16.76 (-0.89), FB: 94.17 (-2.78), GOOG: 627.26 (+3.70), CELG: 132.56 (-2.34), NFLX: 106.43 (-2.91), AGN: 326.98 (+18.77), T: 34.32 (+0.03), GILD: 110.54 (-2.29), S: 3.10 (-0.34), DTV: 93.55 (+1.36), GM: 31.05 (-0.01), TMUS: 36.50 (-0.90), TWTR: 34.70 (-0.72), VZ: 45.83 (-0.21), REGN: 540.03 (-1.82)
Biogen's Big-Volume Plunge Marks End Of 5-Year Run
at Investor's Business Daily - Fri Jul 24, 12:26PM CDT
Biogen's (BIIB) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech's quarterly revenue growth to come in well below consensus estimates. The company also cut its...
BIIB: 309.43 (+9.40), VRX: 257.30 (+5.38), LLY: 84.15 (-0.57), ABBV: 69.34 (+1.26), BMY: 64.30 (-1.68), CELG: 132.56 (-2.34)
When Leader Goes Down, Whole Sector Feels It
at The Street - Fri Jul 24, 10:24AM CDT
Biogen's weak numbers leave biotechs ailing.
BIIB: 309.43 (+9.40), COF: 78.61 (-0.25), GILD: 110.54 (-2.29), RCPT: 227.09 (-0.91), REGN: 540.03 (-1.82), CELG: 132.56 (-2.34)
Stocks Open Mixed And Wild; Maxim, Visa, Amazon Spike
at Investor's Business Daily - Fri Jul 24, 9:39AM CDT
Stocks set out in a tightly-mixed start Friday, with both the Nasdaq and S&P 500 trading about 1% lower so far for the week. The Nasdaq pulled up 0.3%. The Dow Jones industrial average managed a 0.1% gain. The S&P 500 hung out a fractional loss....
AMBA: 119.45 (-4.78), MXIM: 33.85 (+0.28), BIIB: 309.43 (+9.40), AMZN: 531.41 (+1.99), TRIP: 80.60 (-0.26), CELG: 132.56 (-2.34), JNPR: 27.43 (-0.11), CI: 145.90 (+0.18), ANTM: 151.50 (+0.64), V: 73.86 (-0.94), SAVE: 59.78 (-0.55), COF: 78.61 (-0.25), AAL: 40.14 (+0.51)
Celgene Delivers as Expected in Q2, but Raises New Questions
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 24, 9:10AM CDT
Source: Food and Drug Administration via Facebook. Biotech blue-chip stock Celgene (NASDAQ: CELG) knows only one gear when it comes to earnings season: overdrive. With the exception of the fourth-quarter of 2013, Celgene has topped Wall Street's...
CELG: 132.56 (-2.34)
Celgene posts 36% rise in Q2 2015 adjusted net income
M2 - Fri Jul 24, 5:37AM CDT
Biopharmaceutical company Celgene (NasdaqGS:CELG) on Thursday declared its adjusted net income of USD1,019m for the second quarter of 2015 .
CELG: 132.56 (-2.34), CELGZ: 2.00 (-0.06)
Celgene Rolling Along (but You Already Knew That)
Brian Orelli, The Motley Fool - Motley Fool - Thu Jul 23, 1:47PM CDT
The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week. But the details of where the...
RCPT: 227.09 (-0.91), ABBV: 69.34 (+1.26), CELG: 132.56 (-2.34)
Celgene (CELG) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Thu Jul 23, 1:11PM CDT
The following Celgene (CELG) conference call took place on July 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
CELG: 132.56 (-2.34)
Celgene Q2 Earnings & Revenues In Line, Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:26PM CDT
Celgene Corporation (CELG) reported second-quarter 2015 earnings of $1.08 per share (including stock-based compensation expenses and tax adjustments), in line with the Zacks Consensus Estimate.
RCPT: 227.09 (-0.91), JUNO: 47.80 (-2.36), AMAG: 65.07 (-5.37), CELG: 132.56 (-2.34)
Next Resistance Level for Celgene (CELG) is $141.45
Comtex SmarTrend(R) - Thu Jul 23, 10:18AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $137.52 and have already reached the first level of resistance at $139.86. Investors may be interested in a cross of the next upside pivot targets of $141.45 and $145.38.
CELG: 132.56 (-2.34)
Uptrend Call Working As Celgene Stock Rises 18.8% (CELG)
Comtex SmarTrend(R) - Thu Jul 23, 10:05AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on June 19th, 2015 at $117.12. In approximately 1 month, Celgene has returned 18.80% as of today's recent price of $139.14.
CELG: 132.56 (-2.34)
Valeant Earnings Soar On M&A, Organic Sales Growth
at Investor's Business Daily - Thu Jul 23, 8:37AM CDT
Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts' second-quarter revenue and earnings expectations. Valeant was one...
ENDP: 85.81 (+0.42), VRX: 257.30 (+5.38), SHPG: 259.11 (+6.54), RCPT: 227.09 (-0.91), LLY: 84.15 (-0.57), BMY: 64.30 (-1.68), CELG: 132.56 (-2.34)
